<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Anaptysbio Inc — News on 6ix</title>
<link>https://6ix.com/company/anaptysbio-inc</link>
<description>Latest news and press releases for Anaptysbio Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 24 Apr 2026 19:40:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/anaptysbio-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835463378dffbe2df0e2e13.webp</url>
<title>Anaptysbio Inc</title>
<link>https://6ix.com/company/anaptysbio-inc</link>
</image>
<item>
<title>Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim</title>
<link>https://6ix.com/company/anaptysbio-inc/news/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim</link>
<guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim</guid>
<pubDate>Fri, 24 Apr 2026 19:40:00 GMT</pubDate>
<description>Ruling preserves current contracted royalty rates and rejects Tesaro’s request for any royalty reductionTrial to adjudicate Anaptys’ contract claims and right to seek reversion of Jemperli against Tesaro/GSK is scheduled for July 14-17, 2026 SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that the Delaware Chancery Court has dismissed Tesaro’</description>
</item>
<item>
<title>Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations</title>
<link>https://6ix.com/company/anaptysbio-inc/news/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations</link>
<guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations</guid>
<pubDate>Mon, 20 Apr 2026 13:15:00 GMT</pubDate>
<description>Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholdersLaunches with virtual model, including limited FTEs and minimal operating expenses, and approximately $140-$145 million in net cash SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of its spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business. Anaptys will now exclusively manage</description>
</item>
<item>
<title>First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement</title>
<link>https://6ix.com/company/anaptysbio-inc/news/first-tracks-biotherapeutics-the-planned-spin-off-of-anaptys-secures-commitments-of-dollar145-million-in-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/first-tracks-biotherapeutics-the-planned-spin-off-of-anaptys-secures-commitments-of-dollar145-million-in-private-placement</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>Inclusive of $80 million in proceeds from private placement by leading investorsFirst Tracks Biotherapeutics to launch with $180 million in cash and two-year</description>
</item>
<item>
<title>Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics</title>
<link>https://6ix.com/company/anaptysbio-inc/news/anaptys-board-of-directors-approves-spin-off-of-first-tracks-biotherapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-board-of-directors-approves-spin-off-of-first-tracks-biotherapeutics</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>Board sets spin-off distribution date for First Tracks Biotherapeutics: expected to occur April 20, 2026, pre-marketStockholders will receive one share of</description>
</item>
<item>
<title>Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update</title>
<link>https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-dollar100-million-stock-repurchase-plan-and-provides-a-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-dollar100-million-stock-repurchase-plan-and-provides-a-business-update</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026Anaptys to manage the financial</description>
</item>
<item>
<title>Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/anaptysbio-inc/news/anaptys-provides-update-on-business-separation-and-announces-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-provides-update-on-business-separation-and-announces-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Tue, 03 Mar 2026 21:15:00 GMT</pubDate>
<description>Spin-off of biopharma operations into a public company to be called “First Tracks Biotherapeutics” on track for Q2 2026, potentially as early as late-AprilPhase 1b enrollment ongoing in celiac disease and trial cohort initiated in eosinophilic esophagitis for ANB033, a CD122 antagonistGSK announced strong commercial performance for Jemperli, growing >13% quarter-over-quarter to $343 million in Q4 2025, implying a ~$1.4 billion annualized run rateExpect to achieve >$390 million in annualized Jemp</description>
</item>
<item>
<title>Anaptys Announces Participation at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-participation-upcoming-investor-211500820</link>
<guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-participation-upcoming-investor-211500820</guid>
<pubDate>Thu, 05 Feb 2026 21:15:00 GMT</pubDate>
<description>SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: Guggenheim Emerging Outlook: Biotech Summit 2026, New York, NY Format – Fireside chat and 1x1 investor meetingsDat</description>
</item>
<item>
<title>Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary</title>
<link>https://6ix.com/company/anaptysbio-inc/news/anaptys-files-motion-dismiss-tesaro-230000539</link>
<guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-files-motion-dismiss-tesaro-230000539</guid>
<pubDate>Thu, 08 Jan 2026 23:00:00 GMT</pubDate>
<description>Trial to resolve all claims in the Anaptys and Tesaro/GSK dispute is scheduled for July 14-17, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, filed a partial motion to dismiss Tesaro’s anticipatory breach of contract claim in Delaware Chancery Court related to pending litigation between Anaptys, GSK, and TESARO, Inc. (“Tesaro”) regarding their Collaboration and Exc</description>
</item>
<item>
<title>Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/anaptysbio-inc/news/anaptys-present-44th-annual-jp-morgan-healthcare-conference-2026-01-06</link>
<guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-present-44th-annual-jp-morgan-healthcare-conference-2026-01-06</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative</description>
</item>
<item>
<title>Anaptys Announces Participation in December Investor Conferences</title>
<link>https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-participation-december-investor-conferences-2025-11-25</link>
<guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-participation-december-investor-conferences-2025-11-25</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative</description>
</item>
<item>
<title>Anaptys Announces $100 Million Stock Repurchase Plan</title>
<link>https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-100-million-stock-repurchase-plan-2025-11-21</link>
<guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-100-million-stock-repurchase-plan-2025-11-21</guid>
<pubDate>Fri, 21 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative</description>
</item>
<item>
<title>Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary</title>
<link>https://6ix.com/company/anaptysbio-inc/news/anaptys-initiates-litigation-against-tesaro-gsk-subsidiary-2025-11-21</link>
<guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-initiates-litigation-against-tesaro-gsk-subsidiary-2025-11-21</guid>
<pubDate>Fri, 21 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative</description>
</item>
<item>
<title>Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis</title>
<link>https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-phase-2-trial-rosnilimab-did-not-meet-primary-or-secondary</link>
<guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-phase-2-trial-rosnilimab-did-not-meet-primary-or-secondary</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>Rosnilimab was safe and well tolerated with similar adverse event rates vs. placeboObserved expected pharmacology, including ~90% depletion of pathogenic T</description>
</item>
<item>
<title>Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-third-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-third-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>Announced intent to separate biopharma operations from substantial royalty assets by YE 2026Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic</description>
</item>
<item>
<title>Anaptys Announces Participation in November Investor Conferences</title>
<link>https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-participation-november-investor-conferences-2025-11-04</link>
<guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-participation-november-investor-conferences-2025-11-04</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative</description>
</item>
<item>
<title>Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation</title>
<link>https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-new-positive-phase-2b-trial-results-rosnilimab-rheumatoid-arthritis</link>
<guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-new-positive-phase-2b-trial-results-rosnilimab-rheumatoid-arthritis</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to</description>
</item>
<item>
<title>Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025</title>
<link>https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-late-breaking-oral-presentation-complete-phase-2b-data-rosnilimab</link>
<guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-late-breaking-oral-presentation-complete-phase-2b-data-rosnilimab</guid>
<pubDate>Mon, 13 Oct 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative</description>
</item>
<item>
<title>Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026</title>
<link>https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-intent-separate-biopharma-operations-substantial-royalty-assets</link>
<guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-intent-separate-biopharma-operations-substantial-royalty-assets</guid>
<pubDate>Mon, 29 Sep 2025 04:00:00 GMT</pubDate>
<description>Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion,</description>
</item>
<item>
<title>Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14</title>
<link>https://6ix.com/company/anaptysbio-inc/news/anaptys-provide-overview-anb033-cd122-antagonist-virtual-investor-event-tuesday-oct</link>
<guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-provide-overview-anb033-cd122-antagonist-virtual-investor-event-tuesday-oct</guid>
<pubDate>Mon, 29 Sep 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative</description>
</item>
<item>
<title>Anaptys Announces Participation in September Investor Conferences</title>
<link>https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-participation-september-investor-conferences-2025-08-27</link>
<guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-participation-september-investor-conferences-2025-08-27</guid>
<pubDate>Wed, 27 Aug 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative</description>
</item>
</channel>
</rss>